Skip to content
Peptidepedia

How to Use Liraglutide: Administration, Reconstitution & Storage (2026)

From Peptidepedia, the trusted peptide wiki.

How to Use / Administration Methods

Liraglutide is supplied in pre-filled, multi-dose injection pens that require no reconstitution or mixing. Both Saxenda and Victoza pens use fine-gauge needles and are designed for self-administration.

Injection Procedure:

  1. Allow the pen to reach room temperature if refrigerated (15 to 30 minutes)
  2. Attach a new pen needle for each injection
  3. Prime the pen by dialing to the flow check symbol and pressing the dose button until a drop appears at the needle tip
  4. Dial to the prescribed dose
  5. Clean the injection site with an alcohol swab
  6. Pinch the skin at the abdomen, thigh, or upper arm
  7. Insert the needle at a 90-degree angle and press the dose button fully
  8. Hold the button for 6 seconds before withdrawing
  9. Do not rub the injection site

Liraglutide can be injected at any time of day, independent of meals, though many users find that evening dosing reduces nausea interference with daytime eating. The injection site should be rotated to prevent lipodystrophy. If a dose is missed, skip it and resume the normal schedule the next day. Do not take a double dose.

Reconstitution, Storage & Prep

Liraglutide requires no reconstitution. Both Victoza and Saxenda are supplied as clear, colorless solutions in pre-filled, multi-dose injection pens ready for immediate use.

Storage:

  • Unused pens: Refrigerate at 2 to 8 degrees C (36 to 46 degrees F). Do not freeze. Protect from light.
  • In-use pens: Store at room temperature (up to 30 degrees C / 86 degrees F) or refrigerated for up to 30 days. Discard after 30 days, even if medication remains.
  • The pen cap should be replaced after each use to protect from light.
  • Do not use if the solution appears cloudy, discolored, or contains particles.

Pen Supplies:

  • Saxenda pen: 18 mg/3 mL (6 mg/mL), delivering doses of 0.6, 1.2, 1.8, 2.4, or 3.0 mg
  • Victoza pen: 18 mg/3 mL (6 mg/mL), delivering doses of 0.6, 1.2, or 1.8 mg
  • Pen needles: NovoFine or NovoTwist disposable needles (not included with pens)

Frequently Asked Questions

Both are GLP-1 receptor agonists made by Novo Nordisk. Liraglutide requires daily injections and produces average weight loss of 6 to 8%, while semaglutide is dosed weekly and delivers roughly 15% weight loss. Semaglutide's structural modifications give it a longer half-life (7 days vs 13 hours), making it more convenient and more potent.

Saxenda contains liraglutide 3.0 mg (daily injection) and Wegovy contains semaglutide 2.4 mg (weekly injection). In the head-to-head STEP 8 trial, Wegovy produced 15.8% weight loss compared to 6.4% with Saxenda over 68 weeks. Both are FDA-approved for chronic weight management.

The most frequent side effects are gastrointestinal: nausea (39%), diarrhea (21%), constipation (19%), and vomiting (16%). These are most pronounced during dose escalation and typically improve over several weeks. Serious but rare side effects include pancreatitis and gallbladder disease.

Liraglutide has the longest post-marketing safety record of any GLP-1 agonist, with data spanning over 15 years since its 2010 approval. The LEADER trial followed 9,340 patients for a median of 3.8 years and demonstrated cardiovascular benefits. A 3-year extension of the SCALE trial confirmed sustained weight loss and reduced progression to type 2 diabetes.

Yes. Victoza is approved for children aged 10 and older with type 2 diabetes (since 2019). Saxenda is approved for adolescents aged 12 and older with obesity (since 2020). A dedicated NEJM trial demonstrated that liraglutide 3.0 mg reduced BMI in adolescents with obesity compared to placebo.

Both contain liraglutide but are approved for different indications and at different doses. Victoza is dosed at 1.2 to 1.8 mg daily for type 2 diabetes, while Saxenda is dosed at 3.0 mg daily for chronic weight management. They should not be used together, and Saxenda should not be used as a diabetes treatment.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). N Engl J Med. 2015;373(1):11-22.
  2. Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016;375(4):311-322.
  3. Davies MJ, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes (SCALE Diabetes). JAMA. 2015;314(7):687-699.
  4. Wadden TA, et al. Liraglutide 3.0 mg and Intensive Behavioral Therapy for Obesity in Primary Care (SCALE IBT). Obesity. 2020;28(3):529-536.
  5. Kelly AS, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020;382(22):2117-2128.
  6. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019;10:155.
  7. Rubino DM, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8). JAMA. 2022;327(2):138-150.
  8. Wadden TA, et al. Weight Maintenance and Additional Weight Loss With Liraglutide After Low-Calorie-Diet-Induced Weight Loss (SCALE Maintenance). Int J Obes. 2013;37(11):1443-1451.
  9. FDA Approval of Saxenda for Weight Management in Patients Aged 12 and Older (2020).
  10. Saxenda (liraglutide) Prescribing Information. Novo Nordisk. 2023.
  11. Victoza (liraglutide) Prescribing Information. Novo Nordisk. 2023.
←Read the full Liraglutide guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”